A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.

Post-Menopausal Osteopenia Clinical Trial

Official title:
A Randomized, Double-blind Study of the Effect of Oral Monthly Bonviva on in Vivo Bone Micro-architecture Parameters in Post-menopausal Women With Osteopenia

Status Completed

Clinical Trial Summary

This 2 arm study will compare the effect of oral Bonviva (150mg, monthly) and placebo on parameters of bone micro-architecture, assessed by CT scan, bone turnover and bone mineral density. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly, and measurements will be taken at baseline, and at intervals over 2 years. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00545207
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	Phase 3
Completion date	September 2010

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00150969` - Vitamin K Supplementation in Post-Menopausal Osteopenia	Phase 3
	Completed	`NCT00129623` - A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia	Phase 4